Trial Profile

Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
Indications Gestational trophoblastic disease
Focus Therapeutic Use

Most Recent Events

05 Oct 2021 Results assessing the activity and safety of camrelizumab plus apatinib as combination therapy in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia, published in the Lancet Oncology.
24 Jul 2021 Status changed from active, no longer recruiting to completed.
17 Apr 2020 Planned End Date changed from 30 Jun 2021 to 8 Aug 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com